Donald Dean
Economist & Technical Analyst, Fibonacci/Gamma Trading
Tempus AI's chart points to $90 and then $100 if it clears the $85 call wall. It broke out of a falling wedge after three bottoms near $41.73, is up 58.9% over 30 sessions and is back above the 0.618 Fibonacci level at $80.41. Options are cheap, with implied volatility of 77 against realized volatility of 85. x.comÂ
Tempus AI looks set for a slow climb higher after rising 78% since July, with options positioning pointing to $65 short term and then $70. The stock is consolidating below the 50% retracement at a volume shelf. Gamma exposure shows a $65 ceiling and $60 floor near term, while open interest puts the long-term average call target at $70. x.comÂ
Tempus AI is one of the highest-conviction setups now, and the widespread doubt about its move is itself bullish. The skepticism was earned by a year of false starts, but clearing $58 should flip sentiment quickly, with a near-term target of $68-$73. A weekly break above $73 sets a medium- to long-term target of $144-$168. Momentum is building on both lower and higher timeframes, while about 38M shares, roughly 28% of the float, are sold short into the breakout. x.com x.com x.comÂ
Tempus AI's 31% short interest adds fuel to its Stage 2 breakout. x.comÂ
Tempus AI is a short idea because the stock is being pumped on recent FDA clearances for its EKG-AI tools, while the revenue from them is far off and may never materialize. x.comÂ
Tempus AI's selloff after it beat and raised guidance looks like a great deal, and a further drop would be a chance to buy more. x.comÂ
Tempus AI may be about to go on a run, and its short interest looks a bit rich. As of June 15, 38M of its 180M shares outstanding were sold short, a roughly $2B position at $54. x.comÂ
Tempus AI may go lower near term because of valuation, leadership reputation and insider selling, despite an amazing business. With about 25% growth expected and profitability uncertain, it is not obviously cheap. Glassdoor reviews matter in medicine's high-trust setting, and ongoing insider sales echo founder patterns that ended badly. The data piece, about 5% of market cap, can earn a high multiple, so the stock looks reasonably priced if adoption continues. x.comÂ
Tempus AI is being repriced because its acquisition of Personalis benefits directly from positive Moderna news, while short covering is still underway. Short interest is about 30 million shares, over eight days of normal 3-5 million share volume, and the three-day surge absorbed under a third of it. A small market cap makes the stock easy to push higher, and bullish divergences on the three-day and weekly charts usually last weeks to months. Resistance sits at 74-76, 80 and 84-86. x.com x.com … Show more
Tempus AI and Caris Life Sciences both represent good value in AI-driven biopharma diagnostics. Tempus has some advantages, but with Caris running faster lately the two have become closer; at about $55 for Tempus and $16 for Caris, Caris was the preference, while the choice between them today is less clear. x.comÂ
Tempus AI is a second- or third-tier genomic lab whose AI story is marketing mumbo jumbo, and its management team are promoters. x.comÂ
Tempus AI could catch a bid as a laggard in the hot medical AI space, and it could catch fire soon. Its setup is getting too hard to ignore, despite plenty of past scars on the name. x.com x.com x.comÂ
